You either must be smoking something high or a newbie to biotech R/D ! The only source of income for ZLCS is from royalty and not from sale of any drugs at this time. ZLCS remains to be a research and development (R/D) until they start making money from sale of a FDA approved drug. As a R/D facility, they will continue to use up funding as needed to keep the research going!
Earning$ in early November should meet if not beat. One thing for sure is that Zalicus is capable of producing revenue. Current royalty agreements are solid and long term. If upcoming data is promising, and I think it will be, then the PP$ will exceed $5 easily.